{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:39Z","timestamp":1788243279060,"version":"build-2803163510"},"reference-count":160,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.59556\/japi.74.1676","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:31:38Z","timestamp":1788240698000},"page":"6-26","source":"Crossref","is-referenced-by-count":0,"title":["Redefining Acid Suppression in Acid Peptic Disorders: The Emerging Role of Prazans"],"prefix":"10.59556","volume":"74","author":[{"given":"Mahesh","family":"Goenka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday C","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"Muthuswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas Kumar","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Kak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"VG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Pratap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parimal","family":"Lawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"BS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravishankar","family":"B","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant Kumar","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasu Praveen Chander","family":"Kanuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(3):","key":"key20260901053122_B1","doi-asserted-by":"crossref","first-page":"295\u2013","DOI":"10.1586\/ecp.09.8","article-title":"Acid peptic diseases: pharmacological approach to treatment.","volume":"2","author":"Mejia","year":"2009;","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"(264):","key":"key20260901053122_B2","doi-asserted-by":"crossref","first-page":"636\u2013","DOI":"10.31729\/jnma.8228","article-title":"Acid peptic disease among patients with acute abdomen visiting the department of emergency medicine in a tertiary care center.","volume":"61","author":"Thapa","year":"2023;","journal-title":"JNMA J Nepal Med Assoc"},{"issue":"(7):","key":"key20260901053122_B3","first-page":"e41994.","article-title":"Effectiveness of omeprazole in acid peptic disease: a real-world, patient-reported outcome measures study.","volume":"15","author":"Jain","year":"2023;","journal-title":"Cureus"},{"issue":"(1):","key":"key20260901053122_B4","first-page":"112615.","article-title":"Acid peptic disorder compass: an Indian expert consensus on comprehensive management.","volume":"17","author":"Sinha","year":"2026;","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"(12):","key":"key20260901053122_B5","doi-asserted-by":"crossref","first-page":"1773\u2013","DOI":"10.1007\/s00228-025-03912-9","article-title":"Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.","volume":"81","author":"Shang","year":"2025;","journal-title":"Eur J Clin Pharmacol"},{"issue":"(3):","key":"key20260901053122_B6","first-page":"185.","article-title":"Current therapeutic approaches in acid peptic disease.","volume":"8","author":"Kumar","year":"2023;","journal-title":"J Inflamm Bowel Dis"},{"issue":"(4):","key":"key20260901053122_B7","doi-asserted-by":"crossref","first-page":"453\u2013","DOI":"10.5056\/jnm21077","article-title":"2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease.","volume":"27","author":"Jung","year":"2021;","journal-title":"J Neurogastroenterol Motil"},{"key":"key20260901053122_B8","first-page":"S0025\u20136196(25)00101-6.","article-title":"Diagnosis and management of gastroesophageal reflux disease: a concise review for clinicians.","author":"Phillips","year":"2025:","journal-title":"Mayo Clin Proc"},{"issue":"(7):","key":"key20260901053122_B9","doi-asserted-by":"crossref","first-page":"1353\u2013","DOI":"10.21474\/IJAR01\/21448","article-title":"Study of prescription pattern in patient with acid peptic disease attending medicine outpatient department in a government tertiary care hospital.","volume":"13","author":"Rathod","year":"2025;","journal-title":"Int J Adv Res"},{"key":"key20260901053122_B10","doi-asserted-by":"crossref","first-page":"988\u2013","DOI":"10.18203\/2349-3933.ijam20183134","article-title":"Prevalence and risk factors of acid peptic ulcer disease at a tertiary care hospital.","volume":"5:","author":"Chavan","year":"2018;","journal-title":"Int J Adv Med"},{"issue":"(11):","key":"key20260901053122_B11","doi-asserted-by":"crossref","first-page":"e0334396.","DOI":"10.1371\/journal.pone.0334396","article-title":"Global temporal trends and projections of gastroesophageal reflux disease prevalence: age-period-cohort analysis 2021.","volume":"20","author":"Xie","year":"2025;","journal-title":"PLoS One"},{"issue":"(2):","key":"key20260901053122_B12","doi-asserted-by":"crossref","first-page":"209\u2013","DOI":"10.1007\/s12664-020-01104-0","article-title":"Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: a meta-analysis and meta-regression study.","volume":"40","author":"Rai","year":"2021;","journal-title":"Indian J Gastroenterol"},{"issue":"(6):","key":"key20260901053122_B13","doi-asserted-by":"crossref","first-page":"458\u2013","DOI":"10.1097\/IO9.0000000000000325","article-title":"A cross-sectional study of demographic profile and incidence of Helicobacter pylori in patients with duodenal ulcer perforation.","volume":"63","author":"Shrestha","year":"2025;","journal-title":"Int J Surg Open"},{"key":"key20260901053122_B14","unstructured":"Indian Medical Association. An approach to APD and its management. [online] Available from: https:\/\/www.ima-india.org\/ima\/pdfdata\/APD-Booklet-Final-Design.pdf [Last accessed August, 2026]."},{"issue":"(1):","key":"key20260901053122_B15","doi-asserted-by":"crossref","first-page":"193\u2013","DOI":"10.1111\/nyas.14473","article-title":"Pharmacologic treatment of GERD: where we are now, and where are we going?","volume":"1482","author":"Scarpignato","year":"2020;","journal-title":"Ann N Y Acad Sci"},{"issue":"(3):","key":"key20260901053122_B16","doi-asserted-by":"crossref","first-page":"159\u2013","DOI":"10.7704\/kjhugr.2023.0040","article-title":"History and pharmacological mechanism of gastric acid-suppressive drugs.","volume":"23","author":"Yeom","year":"2023;","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"issue":"(2):","key":"key20260901053122_B17","doi-asserted-by":"crossref","first-page":"202\u2013","DOI":"10.1590\/s0004-2803.201900000-41","article-title":"Historical perspective of gastroesophageal reflux disease clinical treatment.","volume":"56","author":"Zaterka","year":"2019;","journal-title":"Arq Gastroenterol"},{"key":"key20260901053122_B18","doi-asserted-by":"crossref","first-page":"100198.","DOI":"10.1016\/j.crphar.2024.100198","article-title":"GERD: latest update on acid-suppressant drugs.","volume":"7:","author":"Al-Frejat","year":"2024;","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"key20260901053122_B19","first-page":"1309\u2013","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics,","author":"Wallace","year":"2011.","edition":"12th edition."},{"issue":"(7):","key":"key20260901053122_B20","doi-asserted-by":"crossref","first-page":"649\u2013","DOI":"10.1001\/archinte.159.7.649","article-title":"Importance of pH control in the management of GERD.","volume":"159","author":"Hunt","year":"1999;","journal-title":"Arch Intern Med"},{"issue":"(3):","key":"key20260901053122_B21","doi-asserted-by":"crossref","first-page":"609\u2013","DOI":"10.1007\/s00424-008-0495-4","article-title":"The gastric H, K-ATPase: structure, function, and inhibition.","volume":"457","author":"Shin","year":"2009;","journal-title":"Pflugers Arch"},{"issue":"(2):","key":"key20260901053122_B22","first-page":"399\u2013","article-title":"Assessment of acid suppressants use in hospitalized patients.","volume":"17","author":"Chakraborthy","year":"2020;","journal-title":"IJPPR Human"},{"issue":"(4):","key":"key20260901053122_B23","first-page":"244\u2013","article-title":"The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.","volume":"12","author":"G\u0105siorowska","year":"2017;","journal-title":"Prz Gastroenterol"},{"issue":"(1):","key":"key20260901053122_B24","doi-asserted-by":"crossref","first-page":"25\u2013","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.","volume":"19","author":"Shin","year":"2013;","journal-title":"J Neurogastroenterol Motil"},{"key":"key20260901053122_B25","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report.","author":"Malfertheiner","year":"2022;","journal-title":"Gut"},{"key":"key20260901053122_B26","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8598.1","article-title":"The role of acid inhibition in Helicobacter pylori eradication.","volume":"5:","author":"Scott","year":"2016;","journal-title":"F1000Res"},{"key":"key20260901053122_B27","doi-asserted-by":"crossref","first-page":"1655102.","DOI":"10.3389\/fphys.2025.1655102","article-title":"Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review.","volume":"16:","author":"Qiao","year":"2025;","journal-title":"Front Physiol"},{"issue":"(1):","key":"key20260901053122_B28","doi-asserted-by":"crossref","first-page":"27\u2013","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review.","volume":"11","author":"Strand","year":"2017;","journal-title":"Gut Liver"},{"key":"key20260901053122_B29","doi-asserted-by":"crossref","first-page":"1507812.","DOI":"10.3389\/fphar.2025.1507812","article-title":"Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors.","volume":"16:","author":"Wo\u0142owiec","year":"2025;","journal-title":"Front Pharmacol"},{"issue":"(1):","key":"key20260901053122_B30","first-page":"111\u2013","article-title":"Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG.","volume":"90","author":"Valdovinos-Garc\u00eda","year":"2025;","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"issue":"(12):","key":"key20260901053122_B31","doi-asserted-by":"crossref","first-page":"2616\u2013","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.","volume":"98","author":"Miner","year":"2003;","journal-title":"Am J Gastroenterol"},{"key":"key20260901053122_B32","first-page":"1641\u2013","article-title":"Dexlansoprazole MR in the management of gastroesophageal reflux disease.","volume":"1:","author":"Olsen","year":"2009;","journal-title":"Clin Med Ther"},{"issue":"(2):","key":"key20260901053122_B33","first-page":"000219.","article-title":"Effectiveness of omeprazole versus pantoprazole for symptomatic relief of gastro-esophageal reflux disease (GERD)\/acid peptic disease (APD): a real-world evidence (RWE) study.","volume":"9","author":"Shetty","year":"2024;","journal-title":"Gastroenterol Hepatol Int J"},{"issue":"(10):","key":"key20260901053122_B34","doi-asserted-by":"crossref","first-page":"1585\u2013","DOI":"10.1046\/j.1365-2036.2001.01089.x","article-title":"Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux esophagitis.","volume":"15","author":"Bardhan","year":"2001;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(3):","key":"key20260901053122_B35","doi-asserted-by":"crossref","first-page":"178\u2013","DOI":"10.1046\/j.1523-5378.1999.99274.x","article-title":"Comparative treatment of Helicobacter pylori\u2013positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.","volume":"4","author":"Catalano","year":"1999;","journal-title":"Helicobacter"},{"key":"key20260901053122_B36","doi-asserted-by":"crossref","first-page":"3071\u2013","DOI":"10.1111\/j.1572-0241.2000.03254.x","article-title":"Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial.","volume":"95:","author":"Je","year":"2000;","journal-title":"Am J Gastroenterol"},{"issue":"(4):","key":"key20260901053122_B37","doi-asserted-by":"crossref","first-page":"411\u2013","DOI":"10.1111\/j.1365-2036.1995.tb00399.x","article-title":"Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration\u2014a multicenter study.","volume":"9","author":"Rehner","year":"1995;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(8):","key":"key20260901053122_B38","doi-asserted-by":"crossref","first-page":"910\u2013","DOI":"10.1046\/j.1440-1746.2000.02229.x","article-title":"Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients.","volume":"15","author":"Goh","year":"2000;","journal-title":"J Gastroenterol Hepatol"},{"issue":"(8):","key":"key20260901053122_B39","doi-asserted-by":"crossref","first-page":"1747\u2013","DOI":"10.1111\/j.1572-0241.2006.00686.x","article-title":"Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.","volume":"101","author":"Regula","year":"2006;","journal-title":"Am J Gastroenterol"},{"issue":"(1):","key":"key20260901053122_B40","doi-asserted-by":"crossref","first-page":"19\u2013","DOI":"10.1007\/s00228-008-0576-5","article-title":"Relative potency of proton-pump inhibitors: comparison of effects on intragastric pH.","volume":"65","author":"Kirchheiner","year":"2009;","journal-title":"Eur J Clin Pharmacol"},{"issue":"(52):","key":"key20260901053122_B41","doi-asserted-by":"crossref","first-page":"e27411.","DOI":"10.1097\/MD.0000000000027411","article-title":"Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention.","volume":"100","author":"Lee","year":"2021;","journal-title":"Medicine (Baltimore)"},{"issue":"(10):","key":"key20260901053122_B42","first-page":"37\u2013","article-title":"Effectiveness of rabeprazole and other proton pump inhibitors in managing GERD with varying severity: a retrospective, real-world EMR-based study (POWER GERD Study).","volume":"71","author":"Lawate","year":"2023;","journal-title":"J Assoc Physicians India"},{"issue":"(4):","key":"key20260901053122_B43","first-page":"11\u2013","article-title":"Dyspepsia\u2013the Indian perspective: a cross-sectional study on demographics and treatment patterns of dyspepsia from across India (Power 1.0 study).","volume":"71","author":"Sud","year":"2023;","journal-title":"J Assoc Physicians India"},{"issue":"(4):","key":"key20260901053122_B44","first-page":"653\u2013","article-title":"A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).","volume":"3","author":"Kalaitzakis","year":"2007;","journal-title":"Ther Clin Risk Manag"},{"issue":"(39):","key":"key20260901053122_B45","doi-asserted-by":"crossref","first-page":"e8120.","DOI":"10.1097\/MD.0000000000008120","article-title":"Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis.","volume":"96","author":"Li","year":"2017;","journal-title":"Medicine (Baltimore)"},{"issue":"(4):","key":"key20260901053122_B46","doi-asserted-by":"crossref","first-page":"628\u2013","DOI":"10.1007\/s00535-013-0812-3","article-title":"Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.","volume":"49","author":"Kinoshita","year":"2014;","journal-title":"J Gastroenterol"},{"issue":"(7):","key":"key20260901053122_B47","doi-asserted-by":"crossref","first-page":"959\u2013","DOI":"10.1046\/j.1365-2036.1999.00569.x","article-title":"Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.","volume":"13","author":"Kovacs","year":"1999;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(11):","key":"key20260901053122_B48","doi-asserted-by":"crossref","first-page":"740\u2013","DOI":"10.1016\/j.amjmed.2004.01.008","article-title":"Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.","volume":"116","author":"Peura","year":"2004;","journal-title":"Am J Med"},{"issue":"(1):","key":"key20260901053122_B49","first-page":"e12759.","article-title":"Adverse effects associated with proton pump inhibitor use.","volume":"13","author":"Yibirin","year":"2021;","journal-title":"Cureus"},{"issue":"(2):","key":"key20260901053122_B50","doi-asserted-by":"crossref","first-page":"182\u2013","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use.","volume":"24","author":"Kinoshita","year":"2018;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(5):","key":"key20260901053122_B51","doi-asserted-by":"crossref","first-page":"835\u2013","DOI":"10.1111\/apt.18458","article-title":"Integrated analysis of vonoprazan safety for symptomatic gastroesophageal reflux disease or erosive esophagitis.","volume":"61","author":"Howden","year":"2025;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(11):","key":"key20260901053122_B52","doi-asserted-by":"crossref","first-page":"273\u2013","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments.","volume":"26","author":"Scarpignato","year":"2024;","journal-title":"Curr Gastroenterol Rep"},{"issue":"(2):","key":"key20260901053122_B53","doi-asserted-by":"crossref","first-page":"68\u2013","DOI":"10.59556\/japi.73.0844","article-title":"Association of Physicians of India consensus recommendations for vonoprazan in management of acid peptic disorders.","volume":"73","author":"Upadhyay","year":"2025;","journal-title":"J Assoc Physicians India"},{"issue":"(1):","key":"key20260901053122_B54","doi-asserted-by":"crossref","first-page":"22\u2013","DOI":"10.22271\/chemi.2026.v14.i1a.12651","article-title":"Stability of proton pump inhibitors in various dosage forms: a review.","volume":"14","author":"Deshpande","year":"2026;","journal-title":"Int J Chem Stud"},{"key":"key20260901053122_B55","doi-asserted-by":"crossref","first-page":"11\u2013","DOI":"10.2174\/2589977515666230428140741","article-title":"Tegoprazan as a new remedy for gastrointestinal diseases in comparison with its therapeutic predecessors: a mini-review.","volume":"16:","author":"Anik","year":"2023;","journal-title":"Curr Drug Res Rev"},{"issue":"(1):","key":"key20260901053122_B56","first-page":"1\u2013","article-title":"Redefining GERD management: the emerging role of potassium-competitive acid blockers.","volume":"67","author":"Gunawan","year":"2025;","journal-title":"Gulhane Med J"},{"issue":"(2):","key":"key20260901053122_B57","doi-asserted-by":"crossref","first-page":"109\u2013","DOI":"10.52403\/ijhsr.20260215","article-title":"PRAZANs or PCABs, potassium-competitive acid blockers: a new therapeutic class in acid-related diseases.","volume":"16","author":"Errabaka","year":"2026;","journal-title":"Int J Health Sci Res"},{"issue":"(3):","key":"key20260901053122_B58","doi-asserted-by":"crossref","first-page":"e29\u2013","DOI":"10.59556\/japi.73.0878","article-title":"Vonoprazan in management of refractory gastroesophageal reflux disease: an Indian expert group consensus statement.","volume":"73","author":"Abraham","year":"2025;","journal-title":"J Assoc Physicians India"},{"issue":"(6):","key":"key20260901053122_B59","doi-asserted-by":"crossref","first-page":"437\u2013","DOI":"10.1007\/s11894-010-0149-5","article-title":"Novel approaches to inhibition of gastric acid secretion.","volume":"12","author":"Sachs","year":"2010;","journal-title":"Curr Gastroenterol Rep"},{"issue":"(3):","key":"key20260901053122_B60","doi-asserted-by":"crossref","first-page":"334\u2013","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases.","volume":"24","author":"Oshima","year":"2018;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(34):","key":"key20260901053122_B61","doi-asserted-by":"crossref","first-page":"5097\u2013","DOI":"10.3748\/wjg.v25.i34.5097","article-title":"Optimizing proton pump inhibitors in Helicobacter pylori treatment: old and new tricks to improve effectiveness.","volume":"25","author":"Ierardi","year":"2019;","journal-title":"World J Gastroenterol"},{"key":"key20260901053122_B62","doi-asserted-by":"crossref","first-page":"211\u2013","DOI":"10.1007\/5584_2019_367","article-title":"Current and future treatment of Helicobacter pylori infections.","volume":"1149:","author":"Matsumoto","year":"2019;","journal-title":"Adv Exp Med Biol"},{"issue":"(7):","key":"key20260901053122_B63","doi-asserted-by":"crossref","first-page":"e2419818.","DOI":"10.1001\/jamanetworkopen.2024.19818","article-title":"Navigating drug interactions with proton pump inhibitors.","volume":"7","author":"Tan","year":"2024;","journal-title":"JAMA Netw Open"},{"issue":"(4):","key":"key20260901053122_B64","doi-asserted-by":"crossref","first-page":"277\u2013","DOI":"10.4103\/ijp.ijp_198_24","article-title":"Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: the need of the hour.","volume":"56","author":"Chenchula","year":"2024;","journal-title":"Indian J Pharmacol"},{"key":"key20260901053122_B65","doi-asserted-by":"crossref","first-page":"119\u2013","DOI":"10.2147\/CEG.S121056","article-title":"Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.","volume":"11:","author":"Mermelstein","year":"2018;","journal-title":"Clin Exp Gastroenterol"},{"issue":"(2):","key":"key20260901053122_B66","doi-asserted-by":"crossref","first-page":"33.","DOI":"10.3390\/gidisord7020033","article-title":"Updates in gastroesophageal reflux disease management: from proton pump inhibitors to dietary and lifestyle modifications.","volume":"7","author":"Bucan","year":"2025;","journal-title":"Gastrointest Disord"},{"key":"key20260901053122_B67","doi-asserted-by":"crossref","first-page":"1523399.","DOI":"10.3389\/fphar.2025.1523399","article-title":"Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review.","volume":"16:","author":"Ibrahim","year":"2025;","journal-title":"Front Pharmacol"},{"issue":"(6):","key":"key20260901053122_B68","doi-asserted-by":"crossref","first-page":"528\u2013","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors.","volume":"10","author":"Shin","year":"2008;","journal-title":"Curr Gastroenterol Rep"},{"key":"key20260901053122_B69","first-page":"379\u2013","article-title":"Patient satisfaction with proton-pump inhibitors in a tertiary care teaching hospital.","author":"Prabahar","year":"2018;","journal-title":"Indian J Pharm Sci"},{"issue":"(4):","key":"key20260901053122_B70","doi-asserted-by":"crossref","first-page":"657\u2013","DOI":"10.1185\/030079906X100032","article-title":"Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study.","volume":"22","author":"Jones","year":"2006;","journal-title":"Curr Med Res Opin"},{"issue":"(5):","key":"key20260901053122_B71","doi-asserted-by":"crossref","first-page":"1250\u2013","DOI":"10.1053\/j.gastro.2019.12.014","article-title":"Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms.","volume":"158","author":"Delshad","year":"2020;","journal-title":"Gastroenterology"},{"issue":"(3):","key":"key20260901053122_B72","doi-asserted-by":"crossref","first-page":"309\u2013","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease.","volume":"21","author":"Dickman","year":"2015;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(3):","key":"key20260901053122_B73","doi-asserted-by":"crossref","first-page":"411\u2013","DOI":"10.1007\/s40801-025-00497-8","article-title":"Assessment of burden of partial response to standard doses of proton pump inhibitors in patients with clinically diagnosed gastroesophageal reflux disease: a real-world evidence study in India.","volume":"12","author":"Garje","year":"2025;","journal-title":"Drugs Real World Outcomes"},{"issue":"(4):","key":"key20260901053122_B74","first-page":"11.","article-title":"Nocturnal acid breakthrough: approach to management.","volume":"6","author":"Tutuian","year":"2004;","journal-title":"MedGenMed"},{"issue":"(1):","key":"key20260901053122_B75","first-page":"97918.","article-title":"Insight into global burden of gastroesophageal reflux disease: understanding its reach and impact.","volume":"16","author":"Wickramasinghe","year":"2025;","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"(47):","key":"key20260901053122_B76","doi-asserted-by":"crossref","first-page":"e27944.","DOI":"10.1097\/MD.0000000000027944","article-title":"The influence of pretreatment with PPI on Helicobacter pylori eradication: a systematic review and meta-analysis.","volume":"100","author":"Kuang","year":"2021;","journal-title":"Medicine (Baltimore)"},{"issue":"(1):","key":"key20260901053122_B77","doi-asserted-by":"crossref","first-page":"2.","DOI":"10.1038\/s44355-024-00012-w","article-title":"Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: a systematic review.","volume":"2","author":"Gries","year":"2025;","journal-title":"NPJ Gut Liver"},{"issue":"(6):","key":"key20260901053122_B78","doi-asserted-by":"crossref","first-page":"264.","DOI":"10.3390\/jcdd10060264","article-title":"Concomitant use of antiplatelet agents and proton-pump inhibitors increases the risk of adverse cardiovascular events: a nationwide population-based cohort study using balanced operational definitions.","volume":"10","author":"Yang","year":"2023;","journal-title":"J Cardiovasc Dev Dis"},{"issue":"(12):","key":"key20260901053122_B79","doi-asserted-by":"crossref","first-page":"2624\u2013","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.","volume":"8","author":"Siller-Matula","year":"2010;","journal-title":"J Thromb Haemost"},{"issue":"(12):","key":"key20260901053122_B80","first-page":"693\u2013","article-title":"Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders.","volume":"18","author":"Wong","year":"2022;","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"key20260901053122_B81","unstructured":"Central Drugs Standard Control Organisation. CDSCO approved drugs\/vaccines\/r-DNA\/blood products. [online] Available from: https:\/\/cdscoonline.gov.in\/CDSCO\/cdscoDrugs [Last accessed March, 2026]."},{"issue":"(7):","key":"key20260901053122_B82","doi-asserted-by":"crossref","first-page":"63\u2013","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers\u2014are they the next generation of proton pump inhibitors?.","volume":"9","author":"Rawla","year":"2018;","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"key20260901053122_B83","doi-asserted-by":"crossref","first-page":"1477633.","DOI":"10.3389\/fphar.2024.1477633","article-title":"Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis.","volume":"15:","author":"Zhu","year":"2025;","journal-title":"Front Pharmacol"},{"issue":"(2):","key":"key20260901053122_B84","doi-asserted-by":"crossref","first-page":"275\u2013","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility.","volume":"364","author":"Takahashi","year":"2018;","journal-title":"J Pharmacol Exp Ther"},{"issue":"(2):","key":"key20260901053122_B85","doi-asserted-by":"crossref","first-page":"275\u2013","DOI":"10.1007\/s10388-025-01181-0","article-title":"A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease.","volume":"23","author":"Koo","year":"2026;","journal-title":"Esophagus"},{"key":"key20260901053122_B86","unstructured":"US Food and Drug Administration. VOQUEZNA (vonoprazan) tablets, for oral use. [online] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215151s000lbl.pdf [Last accessed March, 2026]."},{"key":"key20260901053122_B87","unstructured":"Takeda Pharmaceutical Company Limited. TAKECAB\u00ae now available for the treatment of acid-related diseases in Japan. [online] Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2015\/takecab-now-available-for-the-treatment-of-acid-related-diseases-in-japan\/ [Last accessed August, 2026]."},{"key":"key20260901053122_B88","article-title":"Marketing approval of tegoprazan in China for Helicobacter pylori eradication therapy.","author":"RaQualia Pharma Inc."},{"issue":"(3):","key":"key20260901053122_B89","doi-asserted-by":"crossref","first-page":"934\u2013","DOI":"10.1111\/cts.12958","article-title":"Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.","volume":"14","author":"Yoon","year":"2021;","journal-title":"Clin Transl Sci"},{"issue":"(11):","key":"key20260901053122_B90","doi-asserted-by":"crossref","first-page":"7843\u2013","DOI":"10.1021\/acs.jmedchem.2c00338","article-title":"Structural basis for binding of potassium-competitive acid blockers to the gastric proton pump.","volume":"65","author":"Tanaka","year":"2022;","journal-title":"J Med Chem"},{"issue":"(3):","key":"key20260901053122_B91","first-page":"183\u2013","article-title":"Intraluminal pH of the human gastrointestinal tract.","volume":"46","author":"Fallingborg","year":"1999;","journal-title":"Dan Med Bull"},{"issue":"(7):","key":"key20260901053122_B92","doi-asserted-by":"crossref","first-page":"751\u2013","DOI":"10.1111\/apt.15438","article-title":"Randomized clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"50","author":"Han","year":"2019;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(7):","key":"key20260901053122_B93","doi-asserted-by":"crossref","first-page":"636\u2013","DOI":"10.1111\/apt.13121","article-title":"Randomized clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"41","author":"Jenkins","year":"2015;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(2):","key":"key20260901053122_B94","doi-asserted-by":"crossref","first-page":"206\u2013","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"48","author":"Sunwoo","year":"2018;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(7):","key":"key20260901053122_B95","doi-asserted-by":"crossref","first-page":"3288\u2013","DOI":"10.1111\/bcp.15268","article-title":"Nighttime gastric acid control by tegoprazan compared to vonoprazan or esomeprazole.","volume":"88","author":"Yang","year":"2022;","journal-title":"Br J Clin Pharmacol"},{"issue":"(4):","key":"key20260901053122_B96","doi-asserted-by":"crossref","first-page":"e70406.","DOI":"10.1002\/jgh3.70406","article-title":"Tegoprazan in gastroesophageal reflux disease and related acid-mediated conditions: a systematic review and meta-analysis.","volume":"10","author":"Bandyopadhyay","year":"2026;","journal-title":"JGH Open"},{"issue":"(3):","key":"key20260901053122_B97","doi-asserted-by":"crossref","first-page":"294\u2013","DOI":"10.1016\/j.pharmthera.2005.05.005","article-title":"Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.","volume":"108","author":"Andersson","year":"2005;","journal-title":"Pharmacol Ther"},{"key":"key20260901053122_B98","doi-asserted-by":"crossref","first-page":"754849.","DOI":"10.3389\/fphar.2021.754849","article-title":"Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects.","volume":"12:","author":"Hwang","year":"2021;","journal-title":"Front Pharmacol"},{"issue":"(7):","key":"key20260901053122_B99","doi-asserted-by":"crossref","first-page":"930\u2013","DOI":"10.1016\/j.clinthera.2022.06.002","article-title":"Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects.","volume":"44","author":"Moon","year":"2022;","journal-title":"Clin Ther"},{"issue":"(7):","key":"key20260901053122_B100","doi-asserted-by":"crossref","first-page":"864\u2013","DOI":"10.1111\/apt.15185","article-title":"Randomized phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs esomeprazole in patients with erosive esophagitis.","volume":"49","author":"Lee","year":"2019;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(1):","key":"key20260901053122_B101","doi-asserted-by":"crossref","first-page":"72\u2013","DOI":"10.1111\/apt.17255","article-title":"Randomized clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive esophagitis.","volume":"57","author":"Cho","year":"2023;","journal-title":"Aliment Pharmacol Ther"},{"key":"key20260901053122_B102","unstructured":"Sebela Pharmaceuticals. Sebela Pharmaceuticals\u00ae announces positive topline results from Phase 3 TRIUMpH. Program of tegoprazan in GERD. [online] Available from: https:\/\/sebelapharma.com\/assets\/media\/Tegoprazan-BLI5100-P3-PR-04212025-Clean-v6-4.22.25.pdf [Last accessed March, 2026]."},{"issue":"(1):","key":"key20260901053122_B103","doi-asserted-by":"crossref","first-page":"e14969.","DOI":"10.1111\/nmo.14969","article-title":"Comparison of tegoprazan and lansoprazole in patients with erosive esophagitis up to 4 weeks: a multicenter, randomized, double-blind, active-comparator phase 4 trial.","volume":"37","author":"Shin","year":"2025;","journal-title":"Neurogastroenterol Motil"},{"issue":"(1):","key":"key20260901053122_B104","doi-asserted-by":"crossref","first-page":"168.","DOI":"10.1038\/s41598-024-84065-0","article-title":"Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial.","volume":"15","author":"Kang","year":"2025;","journal-title":"Sci Rep"},{"issue":"(4):","key":"key20260901053122_B105","doi-asserted-by":"crossref","first-page":"402\u2013","DOI":"10.1111\/apt.16477","article-title":"Randomized clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.","volume":"54","author":"Kim","year":"2021;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(1):","key":"key20260901053122_B106","doi-asserted-by":"crossref","first-page":"58\u2013","DOI":"10.5056\/jnm22104","article-title":"Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial.","volume":"29","author":"Kim","year":"2023;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(1).","key":"key20260901053122_B107","article-title":"Efficacy and safety of tegoprazan in patients with erosive gastroesophageal reflux disease: a multicountry, prospective, randomized, double-blind, active-controlled, parallel-group study.","volume":"11","author":"Agarwal","year":"2025;","journal-title":"Jpn J Gastroenterol"},{"issue":"(1):","key":"key20260901053122_B108","doi-asserted-by":"crossref","first-page":"e70106.","DOI":"10.1111\/hel.70106","article-title":"Tegoprazan-based triple therapy for Helicobacter pylori eradication: a phase III multicenter randomized clinical trial.","volume":"31","author":"Park","year":"2026;","journal-title":"Helicobacter"},{"issue":"(3):","key":"key20260901053122_B109","doi-asserted-by":"crossref","first-page":"e70134.","DOI":"10.1002\/jgh3.70134","article-title":"Tegoprazan-containing versus proton pump inhibitor-containing therapy for first-line eradication of Helicobacter pylori: a meta-analysis of randomized controlled trials.","volume":"9","author":"Simadibrata","year":"2025;","journal-title":"JGH Open"},{"key":"key20260901053122_B110","article-title":"Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: a nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.","author":"Song","year":"2025.","journal-title":"Chin Med J (Engl)"},{"issue":"(6):","key":"key20260901053122_B111","first-page":"104234.","article-title":"Intravenous proton pump inhibitors vs oral potassium-competitive acid blockers before endoscopic treatment of bleeding peptic ulcers.","volume":"17","author":"Lim","year":"2025;","journal-title":"World J Gastrointest Endosc"},{"issue":"(3):","key":"key20260901053122_B112","doi-asserted-by":"crossref","first-page":"313\u2013","DOI":"10.5056\/jnm23150","article-title":"Efficacy of tegoprazan in patients with functional dyspepsia: a prospective, multicenter, single-arm study.","volume":"30","author":"Huh","year":"2024;","journal-title":"J Neurogastroenterol Motil"},{"key":"key20260901053122_B113","doi-asserted-by":"crossref","first-page":"1076356.","DOI":"10.3389\/fmed.2022.1076356","article-title":"Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: a nationwide cohort study.","volume":"9:","author":"Kim","year":"2023;","journal-title":"Front Med (Lausanne)"},{"issue":"(2):","key":"key20260901053122_B114","first-page":"sfaf400.","article-title":"Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors.","volume":"19","author":"Jang","year":"2025;","journal-title":"Clin Kidney J"},{"key":"key20260901053122_B115","article-title":"Effects of tegoprazan, potassium-competitive acid blocker, on the gastric emptying and postprandial symptoms in healthy humans.","author":"Lim","year":"2024.","journal-title":"Dig Dis Sci"},{"issue":"(4):","key":"key20260901053122_B116","doi-asserted-by":"crossref","first-page":"409\u2013","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations.","volume":"55","author":"Echizen","year":"2016;","journal-title":"Clin Pharmacokinet"},{"key":"key20260901053122_B117","first-page":"4385161.","article-title":"Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial.","volume":"2017:","author":"Mizokami","year":"2017;","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"(7):","key":"key20260901053122_B118","first-page":"e64777.","article-title":"A comprehensive review on the efficacy and safety of vonoprazan in the management of gastric acid-related diseases.","volume":"16","author":"Padwale","year":"2024;","journal-title":"Cureus"},{"issue":"(3):","key":"key20260901053122_B119","doi-asserted-by":"crossref","first-page":"139\u2013","DOI":"10.1177\/87551225231166531","article-title":"Vonoprazan: a new potassium-competitive acid blocker.","volume":"39","author":"St Onge","year":"2023;","journal-title":"J Pharm Technol"},{"key":"key20260901053122_B120","doi-asserted-by":"crossref","first-page":"1756283X17745776.","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.","volume":"11:","author":"Sugano","year":"2018;","journal-title":"Therap Adv Gastroenterol"},{"issue":"(2):","key":"key20260901053122_B121","doi-asserted-by":"crossref","first-page":"174\u2013","DOI":"10.1159\/000497775","article-title":"Efficacy of vonoprazan, a novel potassium\u2013competitive acid blocker, in patients with proton pump inhibitor: refractory acid reflux.","volume":"101","author":"Akiyama","year":"2020;","journal-title":"Digestion"},{"issue":"(10):","key":"key20260901053122_B122","doi-asserted-by":"crossref","first-page":"1016\u2013","DOI":"10.1111\/apt.17728","article-title":"Randomized clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for nonerosive reflux disease.","volume":"58","author":"Fass","year":"2023;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(11).","key":"key20260901053122_B123","article-title":"Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor\u2013resistant gastroesophageal reflux disease.","volume":"99","author":"Gotoh","year":"2020;","journal-title":"Medicine (Baltimore)"},{"issue":"(10):","key":"key20260901053122_B124","doi-asserted-by":"crossref","first-page":"1048\u2013","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.","volume":"43","author":"Kagami","year":"2016;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(2):","key":"key20260901053122_B125","doi-asserted-by":"crossref","first-page":"240\u2013","DOI":"10.1111\/apt.13461","article-title":"Randomized clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive esophagitis.","volume":"43","author":"Ashida","year":"2016;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(2):","key":"key20260901053122_B126","doi-asserted-by":"crossref","first-page":"140\u2013","DOI":"10.1111\/apt.15062","article-title":"Randomized clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive esophagitis.","volume":"49","author":"Oshima","year":"2019;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(9):","key":"key20260901053122_B127","doi-asserted-by":"crossref","first-page":"1439\u2013","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study.","volume":"65","author":"Murakami","year":"2016;","journal-title":"Gut"},{"issue":"(2):","key":"key20260901053122_B128","doi-asserted-by":"crossref","first-page":"112\u2013","DOI":"10.37897\/RJID.2025.2.1","article-title":"Efficacy and safety of vonoprazan-amoxicillin for Helicobacter pylori eradication: a pilot study.","volume":"28","author":"Reddy Lankapothu","year":"2025;","journal-title":"Rom J Infect Dis"},{"issue":"(2):","key":"key20260901053122_B129","doi-asserted-by":"crossref","first-page":"e70124.","DOI":"10.1111\/hel.70124","article-title":"Vonoprazan versus tegoprazan-amoxicillin dual therapy for treatment-na\u00efve patients with Helicobacter pylori infection: a prospective, multicenter, open-label, randomized controlled study.","volume":"31","author":"Zhou","year":"2026;","journal-title":"Helicobacter"},{"key":"key20260901053122_B130","article-title":"Vonoprazan is associated with better liver-related outcomes compared with proton pump inhibitors in cirrhosis.","author":"Patel","year":"2026.","journal-title":"Am J Gastroenterol"},{"issue":"(8):","key":"key20260901053122_B131","doi-asserted-by":"crossref","first-page":"1141.","DOI":"10.3390\/ph16081141","article-title":"A comparative pharmacokinetic study of fexuprazan 10 mg: demonstrating bioequivalence with the reference formulation and evaluating steady state.","volume":"16","author":"Shin","year":"2023;","journal-title":"Pharmaceuticals (Basel)"},{"issue":"(44):","key":"key20260901053122_B132","doi-asserted-by":"crossref","first-page":"6294\u2013","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.","volume":"28","author":"Lee","year":"2022;","journal-title":"World J Gastroenterol"},{"issue":"(5):","key":"key20260901053122_B133","doi-asserted-by":"crossref","first-page":"e13798.","DOI":"10.1111\/cts.13798","article-title":"Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy males.","volume":"17","author":"Won","year":"2024;","journal-title":"Clin Transl Sci"},{"issue":"(49).","key":"key20260901053122_B134","article-title":"A review of pharmacological advances in the management of GERD, 2015\u20132025.","volume":"1","author":"Markuszewska","year":"2026;","journal-title":"Int J Innov Technol Soc Sci"},{"issue":"(6):","key":"key20260901053122_B135","doi-asserted-by":"crossref","first-page":"813.","DOI":"10.3390\/pharmaceutics13060813","article-title":"Development of physiologically based pharmacokinetic model for orally administered fexuprazan in humans.","volume":"13","author":"Jeong","year":"2021;","journal-title":"Pharmaceutics"},{"issue":"(1):","key":"key20260901053122_B136","doi-asserted-by":"crossref","first-page":"86\u2013","DOI":"10.5056\/jnm24032","article-title":"Randomized multicenter study to evaluate the efficacy and safety of fexuprazan according to the timing of dosing in patients with erosive esophagitis.","volume":"31","author":"Lee","year":"2025;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(1):","key":"key20260901053122_B137","doi-asserted-by":"crossref","first-page":"19.","DOI":"10.3390\/jpm15010019","article-title":"Preference for on-demand fexuprazan therapy in gastroesophageal reflux disease: a prospective cohort study.","volume":"15","author":"Jung","year":"2025;","journal-title":"J Pers Med"},{"issue":"(1):","key":"key20260901053122_B138","doi-asserted-by":"crossref","first-page":"52\u2013","DOI":"10.5056\/jnm25119","article-title":"Comparison of fexuprazan and esomeprazole for the control of nocturnal gastroesophageal reflux symptoms: a randomized, crossover study.","volume":"32","author":"Oh","year":"2026;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(1):","key":"key20260901053122_B139","doi-asserted-by":"crossref","first-page":"59.","DOI":"10.1007\/s00408-025-00815-5","article-title":"Efficacy and safety of fexuprazan versus esomeprazole for gastroesophageal reflux disease-related chronic cough: a randomized, double-blind, active-controlled exploratory trial.","volume":"203","author":"Kang","year":"2025;","journal-title":"Lung"},{"issue":"(11):","key":"key20260901053122_B140","doi-asserted-by":"crossref","first-page":"5873\u2013","DOI":"10.1007\/s00405-024-08877-6","article-title":"Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial.","volume":"281","author":"Kim","year":"2024;","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"(12):","key":"key20260901053122_B141","doi-asserted-by":"crossref","first-page":"e70082.","DOI":"10.1002\/jgh3.70082","article-title":"Efficacy of vonoprazan 10 mg and 20 mg for patients with proton pump inhibitor-refractory functional dyspepsia: a double-blinded, randomized study.","volume":"8","author":"Bunchorntavakul","year":"2024;","journal-title":"JGH Open"},{"issue":"(5):","key":"key20260901053122_B142","doi-asserted-by":"crossref","first-page":"232\u2013","DOI":"10.14740\/gr2059","article-title":"Efficacy of potassium-competitive acid blockers in functional dyspepsia: a systematic review and meta-analysis.","volume":"18","author":"Nguyen","year":"2025;","journal-title":"Gastroenterol Res"},{"issue":"(3):","key":"key20260901053122_B143","doi-asserted-by":"crossref","first-page":"195\u2013","DOI":"10.1177\/26345161251325874","article-title":"American Foregut Society white paper report on the use of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.","volume":"5","author":"Spechler","year":"2025;","journal-title":"Foregut"},{"issue":"(1):","key":"key20260901053122_B144","doi-asserted-by":"crossref","first-page":"7\u2013","DOI":"10.5056\/jnm25128","article-title":"2025 focused update of the Seoul consensus on gastroesophageal reflux disease: evidence-based recommendations on acid-suppressive therapy.","volume":"32","author":"Huh","year":"2026;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(9):","key":"key20260901053122_B145","doi-asserted-by":"crossref","first-page":"1730\u2013","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection.","volume":"119","author":"Chey","year":"2024;","journal-title":"Am J Gastroenterol"},{"issue":"(4):","key":"key20260901053122_B146","doi-asserted-by":"crossref","first-page":"303\u2013","DOI":"10.1007\/s00535-021-01769-0","article-title":"Evidence-based clinical practice guidelines for peptic ulcer disease 2020.","volume":"56","author":"Kamada","year":"2021;","journal-title":"J Gastroenterol"},{"issue":"(12):","key":"key20260901053122_B147","doi-asserted-by":"crossref","first-page":"34\u2013","DOI":"10.59556\/japi.72.0771","article-title":"Proposed algorithm for the diagnosis and management of functional dyspepsia in India.","volume":"72","author":"Zargar","year":"2024;","journal-title":"J Assoc Physicians India"},{"issue":"(6):","key":"key20260901053122_B148","doi-asserted-by":"crossref","first-page":"707\u2013","DOI":"10.5009\/gnl20246","article-title":"Clinical guidelines for drug-related peptic ulcer, 2020 revised edition.","volume":"14","author":"Joo","year":"2020;","journal-title":"Gut Liver"},{"issue":"(1):","key":"key20260901053122_B149","first-page":"33\u2013","article-title":"Role of Campylobacter pylori and nonsteroidal anti-inflammatory drugs in the pathogenesis of peptic ulcer and pharmacological approaches for the treatment of peptic ulcer disease.","volume":"10","author":"Kumar","year":"2019;","journal-title":"Gastroenterol Hepatol Open Access"},{"issue":"(1):","key":"key20260901053122_B150","doi-asserted-by":"crossref","first-page":"27\u2013","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease.","volume":"117","author":"Katz","year":"2022;","journal-title":"Am J Gastroenterol"},{"issue":"(1):","key":"key20260901053122_B151","first-page":"121\u2013","article-title":"Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda.","volume":"89","author":"Valdovinos D\u00edaz","year":"2024;","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"issue":"(7):","key":"key20260901053122_B152","doi-asserted-by":"crossref","first-page":"1314\u2013","DOI":"10.1016\/j.cgh.2020.03.057","article-title":"Untangling nonerosive reflux disease from functional heartburn.","volume":"19","author":"Patel","year":"2021;","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"(8):","key":"key20260901053122_B153","doi-asserted-by":"crossref","first-page":"2286\u2013","DOI":"10.1053\/j.gastro.2020.01.034","article-title":"AGA clinical practice update on functional heartburn: expert review.","volume":"158","author":"Fass","year":"2020;","journal-title":"Gastroenterology"},{"issue":"(4):","key":"key20260901053122_B154","doi-asserted-by":"crossref","first-page":"267\u2013","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.","volume":"57","author":"Iwakiri","year":"2022;","journal-title":"J Gastroenterol"},{"key":"key20260901053122_B155","doi-asserted-by":"crossref","first-page":"1228\u2013","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review.","volume":"167:","author":"Patel","year":"2024;","journal-title":"Gastroenterology"},{"issue":"(4):","key":"key20260901053122_B156","doi-asserted-by":"crossref","first-page":"599\u2013","DOI":"10.1007\/s40262-023-01228-4","article-title":"Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole.","volume":"62","author":"Yang","year":"2023;","journal-title":"Clin Pharmacokinet"},{"issue":"(9):","key":"key20260901053122_B157","doi-asserted-by":"crossref","first-page":"1519\u2013","DOI":"10.1007\/s12325-016-0374-x","article-title":"Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study.","volume":"33","author":"Sakurai","year":"2016;","journal-title":"Adv Ther"},{"key":"key20260901053122_B158","doi-asserted-by":"crossref","first-page":"5625149.","DOI":"10.1155\/grp\/5625149","article-title":"Efficacy of vonoprazan in nonsteroidal anti-inflammatory drug-induced ulcer in terms of ulcer recurrence and gastrointestinal bleeding: a systematic review and meta-analysis.","volume":"2025:","author":"Bandyopadhyay","year":"2025;","journal-title":"Gastroenterol Res Pract"},{"issue":"(Suppl. 1):","key":"key20260901053122_B159","article-title":"Safety and effectiveness of tegoprazan in patients treated with dual antiplatelet therapy after drug-eluting stent implantation for acute myocardial infarction.","volume":"46","author":"Lee","year":"2025;","journal-title":"Eur Heart J"},{"key":"key20260901053122_B160","doi-asserted-by":"crossref","DOI":"10.7704\/kjhugr.2025.0065","article-title":"Clinical outcomes of tegoprazan versus proton pump inhibitors in patients receiving antiplatelet therapy after percutaneous coronary intervention: a retrospective, observational study.","author":"Lee","year":"2026.","journal-title":"Korean J Helicobacter Up Gastrointest Res"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:32:01Z","timestamp":1788240721000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-8-s1-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":160,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.59556\/japi.74.1676"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1676","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}